Source: Annual Congress 2002 - Isolated lung perfusion and lung cancer
Disease area: Thoracic oncology

Abstract

Aims: to analyse retrospectively the influence of different aspects of systematic lymphadenectomy to long term survival of operated patients, i.e. to investigate whether significant survival differences exist depending on different groups of positive mediastinal nodes, depending on number of analysed nodes or depending on tumour pathology.
Methods: retrospective study including 337 patients who underwent surgical treatment because of primary NSCLC. Patients with incomplete lymphadenectomy were rejected (n=23). Analysis of 5-year and 10-year survival included: N-stage as independent factor, N-stage depending on tumour pathology, N-stage depending on tumour diameter. Particular analysis was made comparing survival in presence of positive subcarinal nodes vs. survival with other positive mediastinal nodes
Results: in the analysed group, lymphadenectomy was based on the analysis of 2, 3 and 4 different nodal groups in 102(30.26%), 74(21.95%) and 45(13.35%) patients respectively. Out of total number of 307 analysed hilar nodes, 99(32.25%) were positive, whilst in the group of 97 analysed interlobar nodes, 21(21.65%) nodes were positive. Percentage of positivity in subcarinal, lower paratracheal, paraoesophageal and anterior mediastinal nodes was 37.71%, 35.72%, 29.31% and 37.71% respectively. Five-year survival worsened from 88.7%, through 68.6% to 59.5% with the increase of N-component from N0 through N1 to N2. The influence of changing N-component to survival in tumours of the same diametter was significantly greater than the influence of changing tumour diameter in presence of the same N-component.

Rating:

Share or cite this content

Citations should be made in the following way:
D. R. Subotic, D. Mandaric, L. Andric (Yugoslavia). Influence of systematic lymphadenectomy to long-term survival in resectable NSCLC. Eur Respir J 2002; 20: Suppl. 38, 1152

Member's Comments

No comment yet.

Related content which might interest you: Comparative evaluation of resectability, postoperative morbidity and mediastinal downstaging after cisplatin-based chemoinduction versus radiochemoinduction for stage III non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 214s Year: 2003 Survival and postoperative complication after neoadjuvant therapy in resectable stage IIIA-N2 non-small cell lung cancer: a balancing exercise Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003 Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer Source: Annual Congress 2011 - General thoracic surgery II Year: 2011 Long-term follow-up comparing postoperative chemotherapy or radiotherapy and surgery with surgery alone in resectable nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 131s Year: 2001 Long-term survival after surgical resection for non-small cell lung cancer Source: International Congress 2017 – Lung cancer: important scientific reports from endoscopists and thoracic surgeons Year: 2017 Treatment of potentially resectable locoregional (stage III) non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005 Factors predicting complete surgical resection after induction chemotherapy in patients with initially unresectable non-small cell lung cancer (NSCLC) treated in a randomised trial Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003 The efficacy of induction chemoradiotherapy followed by surgery in stage IIIA-proven N2 NSCLC and the influence of lymph node downstage on the incidence of postoperative recurrence Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 Chemotherapy plus resection is not better than chemoradiotherapy for baseline unresectable stage IIIA-N2 NSCLC Source: ISSN=ISSN 1810-6838, ISBN=, page=380 Year: 2007 Is there any survival benefit of surgery after neoadjuvant chemoradiotherapy and persisting pn2/3 in stage III NSCLC? Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer Year: 2009 Combination of neoadjuvant and adjuvant chemotherapy in marginally resectable IIIA nonsmall cell lung cancer (NSCLC): long-term follow up Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006 Impact of neoadjuvant therapies on surgical indications and early postoperative outcome Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts Year: 2005 The survival in elderly patients after resection of lung cancer Source: Annual Congress 2008 - Congenital lung lesions and emphysema; lung cancer surgery Year: 2008 Radical radiotherapy in medically inoperable early stage non-small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 318s Year: 2001 Contribution of FDG-PET on staging and management of NSCLC planned for concomitant chemoradiotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 664s Year: 2007 Improved overall survival after late recurrence of lung cancer following the introduction of CT-based follow-up for patients treated with curative intent Source: International Congress 2018 – Lung cancer: from early diagnosis to modern monitoring strategies Year: 2018 Survival impact of surgery in the treatment of stage IIIB-IVA non-small cell lung cancer Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 Survival of patients after complete surgical resection in NSCLC stage IV with solitary metastases Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Trends in mediastinal nodal staging and its impact on unforeseen N2 and survival in lung cancer Source: Eur Respir J, 57 (4) 2001549; 10.1183/13993003.01549-2020 Year: 2021 Surgical treatment of lung cancer after polyhemothetapy/radiotherapy down-staging in patients initially assessed as inoperable Source: Eur Respir J 2006; 28: Suppl. 50, 718s Year: 2006